Daniel Bensen
Fondateur chez TYRA BIOSCIENCES, INC.
Fortune : 7 M $ au 30/04/2024
Postes actifs de Daniel Bensen
Sociétés | Poste | Début | Fin |
---|---|---|---|
TYRA BIOSCIENCES, INC. | Fondateur | 02/08/2018 | - |
Directeur des opérations | 01/11/2018 | - | |
Directeur/Membre du Conseil | 01/11/2018 | 01/01/2020 |
Historique de carrière de Daniel Bensen
Anciens postes connus de Daniel Bensen
Sociétés | Poste | Début | Fin |
---|---|---|---|
CIDARA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2014 | 01/11/2018 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/03/2007 | 01/02/2014 |
Formation de Daniel Bensen
Point Loma Nazarene University | Undergraduate Degree |
USC Marshall School of Business | Masters Business Admin |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
TYRA BIOSCIENCES, INC. | Health Technology |
CIDARA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Daniel Bensen
- Expérience